Kisqali (Ribociclib)

A new option for postmenopausal women with HR+ (ER+ and/or PR+) HER2- metastatic breast cancer in combination with hormone therapy.

Most common side effects affecting nutrition:

• Nausea/Vomiting
• Fatigue
• Diarrhea/Constipation

Serious side effects:

• QT prolongation (abnormal heartbeat)
• Hepatobiliary toxicity (loss of appetite, fatigue)
• Neutropenia (low WBC, increased risk of infection)
•